Factors predicting osteoporosis treatment initiation in a regionally based cohort

被引:13
作者
Cranney, A. [2 ]
Tsang, J. F. [3 ]
Leslie, W. D. [1 ,3 ]
机构
[1] Univ Manitoba, Dept Internal Med, Winnipeg, MB R2H 2A6, Canada
[2] Ottawa Hlth Res Inst, Ottawa, ON, Canada
[3] Univ Manitoba, Dept Radiol, Winnipeg, MB R2H 2A6, Canada
关键词
Bone densitometry; Dual energy X-ray absorptiometry; Osteoporosis; Pharmacotherapy; T-score; BONE-MINERAL DENSITY; FRACTURE RISK; POSTMENOPAUSAL WOMEN; ABSOLUTE; OSTEOPENIA; DATABASE; TRIAL; BMD; UK;
D O I
10.1007/s00198-008-0823-8
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Osteoporosis treatment initiation was assessed during the year after baseline BMD testing in 8,689 previously untreated women. Treatment initiation increased progressively as BMD T-scores decreased, but there was a gradient response rather than step increases at conventional T-score intervention thresholds. Bone mineral density (BMD) testing is used to identify those at high fracture risk and guide osteoporosis treatment (OTx) initiation. Clinical guidelines have used the World Health Organization T-score diagnostic cutoffs as thresholds for treatment intervention. Our objective was to assess whether OTx initiation tracks these T-score cutoffs. Eight thousand six hundred and eighty-nine women age a parts per thousand yen50 years who had not been dispensed any OTx medication in the year prior to baseline BMD were identified from a regionally based database in the Province of Manitoba, Canada, and OTx initiation rates were analyzed. Forty-four percent of women were dispensed OTx in the year after BMD. OTx initiation increased progressively as BMD T-scores decreased (8.2% normal, 41.0% osteopenic, 78.5% osteoporotic, p-for-trend < 0.0001). There was a gradient response to OTx initiation, rather than step increases at conventional T-score intervention thresholds. BMD was strongly associated with OTx (p < 0.0001) while age, weight, and fracture in the last year were not. Physicians rely heavily on BMD T-score to decide on OTx initiation. Although guidelines suggest using clinical risk factors to guide decision making, we did not see evidence of this. More explicit methods of reporting fracture risk may help physicians select patients who are likely to derive the largest benefit from OTx.
引用
收藏
页码:1621 / 1625
页数:5
相关论文
共 20 条
[1]
ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1
[2]
Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence [J].
Binkley, N ;
Kiebzak, GM ;
Lewiecki, EM ;
Krueger, D ;
Gangnon, RE ;
Miller, PD ;
Shepherd, JA ;
Drezner, MK .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (02) :195-201
[3]
An assessment tool for predicting fracture risk in postmenopausal women [J].
Black, DM ;
Steinbuch, M ;
Palermo, L ;
Dargent-Molina, P ;
Lindsay, R ;
Hoseyni, MS ;
Johnell, O .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (07) :519-528
[4]
Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial [J].
Black, DM ;
Thompson, DE ;
Bauer, DC ;
Ensrud, K ;
Musliner, T ;
Hochberg, MC ;
Nevitt, MC ;
Suryawanshi, S ;
Cummings, SR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4118-4124
[5]
BROWN JP, 2002, SMAJ S, V167, pS1
[6]
Predictive value of BMD for hip and other fractures [J].
Johnell, O ;
Kanis, JA ;
Oden, A ;
Johansson, H ;
De Laet, C ;
Delmas, P ;
Eisman, JA ;
Fujiwara, S ;
Kroger, H ;
Mellstrom, D ;
Meunier, PJ ;
Melton, LJ ;
O'Neill, T ;
Pols, H ;
Reeve, J ;
Silman, A ;
Tenenhouse, A .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (07) :1185-1194
[7]
Case finding for the management of osteoporosis with FRAX® -: assessment and intervention thresholds for the UK [J].
Kanis, J. A. ;
McCloskey, E. V. ;
Johansson, H. ;
Strom, O. ;
Borgstrom, F. ;
Oden, A. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (10) :1395-1408
[8]
FRAX™ and the assessment of fracture probability in men and women from the UK [J].
Kanis, J. A. ;
Johnell, O. ;
Oden, A. ;
Johansson, H. ;
McCloskey, E. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :385-397
[9]
Assessment of fracture risk [J].
Kanis, JA ;
Borgstrom, F ;
De Laet, C ;
Johansson, H ;
Johnell, O ;
Jonsson, B ;
Oden, A ;
Zethraeus, N ;
Pfleger, B ;
Khaltaev, N .
OSTEOPOROSIS INTERNATIONAL, 2005, 16 (06) :581-589
[10]
Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial [J].
Kanis, JA ;
Johnell, O ;
Black, DM ;
Downs, RW ;
Sarkar, S ;
Fuerst, T ;
Secrest, RJ ;
Pavo, I .
BONE, 2003, 33 (03) :293-300